← Eichor
Condition: Pd L1 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Pd L1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-0
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT06961006Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Phase 3 · 1 location(s) · Akeso · NCT06928389Montreal Immune-Related Adverse Events (MIRAE) Study
Phase N/A · 1 location(s) · Sir Mortimer B. Davis - Jewish General Hospital · NCT05139706This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and
Phase 1 · 8 location(s) · ABL Bio, Inc. · NCT04762641Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAK
Phase 2 · 38 location(s) · Merck Sharp & Dohme LLC · NCT06788912Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05397769Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous
Phase 2 · 1 location(s) · Xiuping Ding · NCT07055841A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Phase 1/Phase 2 · 1 location(s) · Akeso · NCT06642792HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
Phase 2 · 1 location(s) · HC Biopharma Inc. · NCT07169552A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With An
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT06827236A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · 419 location(s) · Eli Lilly and Company · NCT06119581Impact of Circadian Rhythm on Immunotherapy
Phase 2 · 1 location(s) · Liza Villaruz, MD · NCT07224971Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06001658An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Phase 1 · 7 location(s) · FBD Biologics Limited · NCT06487624Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Phase 2 · 14 location(s) · Hospital Israelita Albert Einstein · NCT05492123Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic
Phase 1/Phase 2 · 1 location(s) · Joachim Aerts, MD PhD · NCT05927142Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metast
Phase 2 · 2 location(s) · Queen Mary University of London · NCT06954480Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03907475Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06769971Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Ad
Phase 2 · 20 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07176312Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
NA · 1 location(s) · Ruijin Hospital · NCT05552846Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT03949231Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With
Phase 2 · 1 location(s) · Fudan University · NCT07100392Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161532A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Phase 3 · 45 location(s) · Takeda · NCT07217301PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT04539977Biomarkers in Immunotherapy of Melanoma
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT05878977A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors
EARLY_Phase 1 · 2 location(s) · Shanghai Henlius Biotech · NCT07274813Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Phase 1 · 1 location(s) · Sichuan University · NCT06348797CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05410717
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.